Purchase Order 75N91019P00291

<p>The National Cancer Institute awarded a purchase order to Qiagen, LLC for $11,414.00 on March 20, 2018, with an ultimate completion date of April 20, 2018. No set-aside was used. Place of performance is Bethesda, Maryland. The purchase order is a firm fixed price commercial transaction. The specific commodity or service being procured is not detailed in the source.</p>

<p>The National Cancer Institute awarded a purchase order to Qiagen, LLC for $24,480.00 on March 30, 2020, with performance completion by March 31, 2021. Work is performed in Bethesda, Maryland. This firm fixed-price purchase order acquired molecular diagnostics products or services—specific scope details are not provided in the award documentation.</p>

<p>The National Cancer Institute awarded a purchase order to Qiagen, LLC for $24,480 on June 9, 2020, with an ultimate completion date of June 14, 2021. Work is performed in Germantown, Maryland. The order is firm fixed price with no set-aside category. No additional source material specifies the scope of services or supplies procured under this purchase order.</p>

<p>The National Cancer Institute awarded a purchase order to Qiagen, LLC valued at $3,684.00 on June 27, 2017, with an ultimate completion date of June 23, 2018. Performance occurs in Bethesda, Maryland. The order is priced on a firm fixed price basis with no set-aside designation applied.</p>

<p>The National Cancer Institute awarded a purchase order to Qiagen, LLC for $23,000.00 on September 3, 2019, with an ultimate completion date of September 3, 2020. The order procures Product #830685QCII Large Panel Sub 1 under firm fixed price terms. Performance is at Qiagen's Germantown, Maryland location. No set-aside applies to this acquisition.</p>

The National Cancer Institute awarded a purchase order to Qiagen, LLC for $4,995.00 on January 26, 2018, with completion scheduled for January 31, 2019. No set-aside was used. Performance takes place in Bethesda, Maryland. The order calls for firm fixed-price procurement of molecular diagnostics, scientific equipment, or bioinformatics solutions consistent with Qiagen's federal product portfolio of DNA and RNA extraction kits, next-generation sequencing supplies, sample preparation...

<p>The National Cancer Institute issued a purchase order to Qiagen, LLC for sample testing with a ceiling value of $24,000.00 on July 17, 2019. Performance occurs at Bethesda, MD 20892. The order carries firm fixed price pricing and is scheduled for ultimate completion July 19, 2020. No set-aside was used.</p>

<p>The National Cancer Institute awarded a purchase order to Qiagen, LLC for $8,337.35 on April 16, 2018, with an ultimate completion date of May 12, 2018. Work is performed in Valencia, California. The order is priced as firm fixed price with no set-aside. The specific requirements are not detailed in the source.</p>

<p>The National Cancer Institute awarded a purchase order to Qiagen, LLC for a QCI subscription valued at $24,000.00 on December 17, 2019, with ultimate completion on July 1, 2020. Place of performance is Germantown, Maryland. The order is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Qiagen, LLC for laboratory supplies valued at $4,368.70 on July 6, 2017, with an ultimate completion date of August 4, 2017. Work is performed in Germantown, Maryland. The order is for QIAGEN lab supplies on a firm fixed price basis with no set-aside used.</p>